Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Wegovy class has higher GI side effect risk than older weight loss drug in study
02:31pm, Thursday, 05'th Oct 2023
Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity dr
Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
11:00am, Thursday, 05'th Oct 2023
The study comes as Novo Nordisk's Wegovy, Ozempic and similar treatments skyrocket in popularity in the U.S. for causing dramatic weight loss over time.
Novo Nordisk's Wegovy and Ozempic US patents to be examined by appeal board
10:44am, Thursday, 05'th Oct 2023
One of Novo Nordisk's (NYSE:NVO) US patents for its blockbuster weight-loss drugs Ozempic and Wegovy will be reviewed by the US Patent Office after it was questioned by generic drugmaker Mylan Pha
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
05:50am, Thursday, 05'th Oct 2023
There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
Focus: Novo Nordisk's Wegovy bonanza looms large in Denmark
01:10am, Thursday, 05'th Oct 2023
The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk , but also for its home country of Denmark.
Novo Nordisk receives US regulatory go ahead for kidney treatment
03:24am, Tuesday, 03'rd Oct 2023
Europe's largest drugs company, Novo Nordisk (NYSE:NVO), told investors its once-monthly injection, Rivfloza, has received approval from the US Food and Drug Administration (FDA) for treating a rare
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
04:54pm, Monday, 02'nd Oct 2023
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by
US FDA approves Novo Nordisk's therapy for rare genetic condition
11:29am, Monday, 02'nd Oct 2023
Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
11:28am, Monday, 02'nd Oct 2023
Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
3 Stocks to Focus on as Demand for Obesity Drugs Booms
11:17am, Friday, 29'th Sep 2023
The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's N
Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats
01:44am, Friday, 29'th Sep 2023
Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top compan
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
08:45am, Thursday, 28'th Sep 2023
The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S
Is Novo Nordisk a Good Passive Income Stock?
05:29am, Thursday, 28'th Sep 2023
Novo Nordisk has the income flow to pay a dividend for the long term. It also has a pipeline full of candidates to keep the growth going.
US prescriptions for Ozempic and other weight loss drugs surged to 9 million in 4Q 2022
01:18pm, Wednesday, 27'th Sep 2023
Ozempic, Wegovy and other diabetes/weight loss drugs were prescribed more than 9 million times in the US during the fourth quarter of 2022, according to a new report. A Trilliant Health analysis of
Novo Nordisk Wegovy surge to continue, says Stifel
10:59am, Wednesday, 27'th Sep 2023
Novo Nordisk (NYSE:NVO)'s stellar growth is unlikely to slow this year, according to Stifel, which was updating its views after a call with the Danish pharma's management. “Our main takeaway is that
